for his work on a Corona vaccine known Mainz-based Biotech company, Biontech has certificates the price for its new issue of shares (American Depository Shares, ADS) and a rights offering to be announced. Accordingly, Biontech wants to sell 5.5 million ADS (initially 5 million planned) at a price of 93 dollars. This will bring the company a gross revenue of 511,5 million dollars. For the purpose of stabilisation of an existing shareholder has granted the underwriters a 30-day Option to purchase additional 825,000 and ADSs.
in Addition, Biontech reference rechtean the holders of the ordinary shares and ADS for a total of about 7.5 million shares of common stock, including those already represented by ADSs. Certain shareholders, who hold about three-quarters of the share capital, have undertaken not to transfer this subscription right or exercise, so that the bulk is likely to go to the free float. For the newly issued ADS there are no subscription rights.The owner of the “Old ADS” will receive the ADS subscription rights, as well as the holders of ordinary shares. 31 ADS subscription rights entitle the holders to purchase one new ADS at a price of 93 dollars. 31Aktien-subscription rights entitle to the acquisition of a new ordinary share to 80,32 Euro.
the Nasdaq-the price of the existing ADS had risen on the eve of 91,60 on 104,17 dollars. Due to the extensive order of the American government for the future vaccine is likely to be
been
